🏛️ Verified NIH Record • Updated 2026-05-04
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (NCT04586231)
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC
🩺 Plain-English Summary (8th-Grade Level)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer & Research Centers ( Site 0077) — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (184 Sites)
Showing the first 25 of 184 sites.
- Ironwood Cancer & Research Centers ( Site 0077) — Chandler, Arizona
- Cedars Sinai Medical Center ( Site 0027) — Los Angeles, California
- UCLA Hematology/Oncology - Santa Monica ( Site 0048) — Los Angeles, California
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095) — Orange, California
- University of California, Irvine ( Site 0029) — Orange, California
- Providence Saint John's Health Center ( Site 0083) — Santa Monica, California
- Georgetown University Medical Center ( Site 0006) — Washington D.C., District of Columbia
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003) — Orlando, Florida
- Orlando Health, Inc. ( Site 0035) — Orlando, Florida
- University Cancer & Blood Center, LLC ( Site 0057) — Athens, Georgia
- Emory University Hospital ( Site 0012) — Atlanta, Georgia
- Rush University Medical Center ( Site 0040) — Chicago, Illinois
- Illinois Cancer Care, PC ( Site 0008) — Peoria, Illinois
- Parkview Cancer Institute ( Site 0088) — Fort Wayne, Indiana
- Norton Cancer Institute - St. Matthews ( Site 0065) — Louisville, Kentucky
- Tulane University School of Medicine ( Site 0098) — New Orleans, Louisiana
- Lahey Hospital & Medical Center ( Site 0090) — Burlington, Massachusetts
- Cancer & Hematology Centers of Western Michigan ( Site 0018) — Grand Rapids, Michigan
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005) — Saint Louis Park, Minnesota
- University of Mississippi Medical Ctr ( Site 0037) — Jackson, Mississippi
- Cancer Partners of Nebraska ( Site 0086) — Lincoln, Nebraska
- Rutgers Cancer Institute of New Jersey ( Site 0078) — New Brunswick, New Jersey
- R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013) — Lake Success, New York
- Memorial Sloan Kettering Cancer Center ( Site 0055) — New York, New York
- Levine Cancer Institute ( Site 0004) — Charlotte, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Renal Cell
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) — San Francisco, California
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) — San Francisco, California
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) — Birmingham, Alabama
- A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) — Phoenix, Arizona
- Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers) — Durham, North Carolina
Explore by condition: All Carcinoma, Renal Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.